Q-omics provides the consensus-scored SUMO2P17 profile across patient tissues and cancer cell-line models. SUMO2P17 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SUMO2P17 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SUMO2P17 RNA expression shows 18,249 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where SUMO2P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUMO2P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUMO2P17 survival associations across molecular data types. SUMO2P17 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUMO2P17 RNA expression–survival associations across cancer types. High SUMO2P17 expression shows unfavorable associations in KIRP, UVM, KICH and ACC, but favorable associations in SKCM and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SUMO2P17 RNA expression.
This table summarizes SUMO2P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SUMO2P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUMO2P17 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BRCA, LIHC and BLCA. The KICH box plot shows higher SUMO2P17 RNA expression in normal versus tumor tissue (log2 FC = −0.971, t-test p < 0.001).
This table shows molecular features associated with SUMO2P17 in patient tissues and cancer cell lines. In patient samples, SUMO2P17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
